Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Inhalers like Spiriva and Advair are too expensive for many Medicare beneficiaries with chronic obstructive pulmonary disease, reports Kaiser Health News. Here are four things to know. 1.

BALTIMORE, Aug. 16, 2023 /PRNewswire/ -- Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium ...

Indian drugmaker Lupin Limited has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for tiotropium bromide inhalation powder, 18 mcg/capsule, a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Lupin’s 18 µg capsules of tiotropium bromide inhalation powder, according to a manufacturer ...

WASHINGTON, Sept 23 (Reuters) - The blockbuster inhaled lung medication Spiriva, marketed by Pfizer Inc and Boehringer Ingelheim, raises the risk of heart attack, stroke and death from heart disease, ...

When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the patient to no more than $35 a month, it came as a shockingly pleasant ...

Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler products for COPD and asthmaExpansive program builds on the company's century-long ...

Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...

(Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker said on ...